Ras farnesyltransferase inhibitors

Drugs of the Future

Volumn 24, Issue 10, 1999, Pages 1099-1106

  Leonard, Daniele M ^a   Sebolt Leopold, Judith S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDYLACETYL)PIPERIDINE; 4 [2 [4 [3,10 DIBROMO 8 CHLORO 6,11 DIHYDRO 5H BENZO(5,6) CYCLOHEPTA[1,2 B]PYRIDIN 11 YL] 1 PIPERIDINYL] 2 OXOETHYL] 1 PIPERIDINECARBOXAMIDE; B 581; BENZODIAZEPINE; BENZYLOXYCARBONYLHISTIDYL(O BENZYLTYROSYL)(O BENZYLSERYL)TRYPTOPHYL DEXTRO ALANINAMIDE; BZA 2B; DIMETHYLALLYLTRANSFERASE; L 731734; L 731735; L 745631; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE METHYL ESTER; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PD 152440; PD 169451; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB; UNCLASSIFIED DRUG;

CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ONCOGENE RAS; REVIEW; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032696858     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.10.858630     Document Type: Review

References (59)

1. Casey, P.J., Solski, P.A., Der, C.J., Buss, J.E. p21 Ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989, 86: 8323-7.
2. Hancock, J.F., Magee, A.I., Chilad, J.E., Marshall, C.J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57: 1167-77.
3. Schafer, W.R., Kim, R., Sterne, R., Thorner, J., Kim, S-H., Rine, J. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 1989, 245: 379-85.
4. Reiss, Y., Seabra, M.C., Goldstein, J.L., Brown, M.S. Purification of ras farnesyl protein transferase. Methods: A Companion to Methods in Enzymology 1990, 1: 241-5.
5. Reiss, Y., Goldstein, J.L., Seabra, M.C., Casey, P.J., Brown, M.S. Inhibition of purified p21 ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 1990, 62: 81-8.
6. Ashby, M.N., King, D.S., Rine, J. Endoproteolytic processing of a farnesylated peptide in vitro. Proc Natl Acad Sci USA 1992, 89: 4613-7.
7. Ma, Y-T., Rando, R.R. A microsomal endoprotease that specifically cleaves isoprenylated peptides. Proc Natl Acad Sci USA 1992, 89: 6275-9.
8. Boyartchuk, V.L., Rine, J. Roles of prenyl protein proteases in maturation of Saccharomyces cerevisiae α-factor. Genetics 1998, 150: 95-101.
9. Otto, J.C., Kim, E., Young, S.G., Casey, P.J. Cloning and characterization of a mammalian prenyl protein specific protease. J Biol Chem 1999, 274: 8379-82.
10. Clarke, S., Vogel, J.P., Deschenes, R.J., Stock, J. Posttranslational modification of the Ha-ras oncogene protein: Evidence for a third class of protein carboxyl methyltransferases. Proc Natl Acad Sci USA 1988, 85: 4643-6.
11. Perez-Sala, D., Tan, E.W., Canada, F.J., Rando, R.R. Methylation and demethylation reactions of guanine nucleotidebinding proteins of retinal rod outer segments. Proc Natl Acad Sci USA 1991, 88, 3043-6.
12. Liu, L., Dudler, T., Gelb, M.H. Purification of a protein palmitoyl transferase that acts on H-Ras protein and on C-terrninal N-ras peptide. J Biol Chem 1996, 271: 23269-76.
13. Ghomashchi, F., Zhang, X., Liu, L., Gelb, M. Binding of prenylated and polybasic peptides to membranes: Affinities and intervesicle exchange. Biochemistry 1995, 34: 11910-8.
14. Park, H., Boduliri, S., Moomaw, J., Casey, P., Beese, L. Crystal structure of protein farnesyl transferase at 2.25 Å resolution. Science 1997, 275: 1800-4.
15. Strickland, C.L., Windsor, W.T., Syto, R. et al. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry 1998, 37: 16601-11.
16. Barbacid, M. The ras oncogen. Annu Rev Biochem 1987, 56: 779-828.
17. Sepp-Lorenzino, L., Ma, Z., Rands, E. et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res 1995, 55: 5302-9.
18. Du, W., Lebowitz, P.F., Prendergast, G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 1999, 19: 1831-40.
19. Leonard, D.M. Ras farnesyltransferase: A new therapeutic target. J Med Chem 1997, 30: 2971-90.
20. Williams, T.M. Inhibitors of protein farnesylation 1998. Exp Opin Ther Patents 1998, 8: 553-69.
21. Goldstein, J.L., Brown, M.S., Stradley, S.J., Reiss, Y., Gierasch, L.M. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J Biol Chem 1991, 266: 15575-8.
22. Kohl, N. E., Mosser, S.D., de Solms, S.J. et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993, 260: 1934-7.
23. Graham, S.L., de Solms, S.J., Giuliani, E.A. et al. Pseudopeptide inhibitors of ras farnesyl-protein transferase. J Med Chem 1994, 37: 725-32.
24. Kohl, N.E., Wilson, F.R., Mosser, S.D. et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 1994, 91: 9141-5.
25. Prendergast, G.C., Davide, J.P., de Solms, S.J. et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 1994, 14: 4193-202.
26. Kohl, N.E., Omer, C.A., Conner, M.W. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995, 1: 792-7.
27. Barrington, R.E., Subler, M.A., Rands, E. et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 1998, 18: 85-92.
28. Garcia, A.M., Rowell, C., Ackermann, K., Kowalczyk, J.J., Lewis, M.D. Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J Biol Chem 1993, 268: 18415-8.
29. Cox, A.D., Garcia, A.M., Westwick, J.K. et al. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J Biol Chem 1994, 269: 19203-6.
30. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M.D., Garcia, A.M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 1995, 55: 5310-4.
31. James, G.L., Goldstein, J.L., Brown, M.S. et al. Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 1993, 260: 1937-42.
32. James, G.L., Brown, M.S., Cobb, M.H., Goldstein, J.L. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-ras-transformed rat-1 cells, but not in untransformed cells. J Biol Chem 1994, 269: 27705-14.
33. Dalton, M.B., Fantle, K.S., Bechtold, H.A. et al. The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21 ras but does not affect their function or localization. Cancer Res 1995, 55: 3295-304.
34. 2X peptidomimetics. J Biol Chem 1993, 268:20695-8.
35. Qian, Y., Blaskovich, M.A., Saleem, M. et al. Design and structural requirements of potent peptidomimetic inhibitors of p21 ras farnesyltransferase. J Biol Chem 1994, 269: 12410-3.
36. Qian, Y., Blaskovich, M.A., Seong, C-M., Vogt, A., Hamilton, A.D., Sebti, S.M. Peptidomimetic inhibitors of p21 ras farnesyl transferase: Hydrophobic functionalization leads to disruption of p21 ras membrane association in whole cells. Bioorg Med Chem Lett 1994, 4: 2579-84.
37. Lerner, E.C., Qian, Y., Blaskovich, M.A. et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive ras-raf complexes. J Biol Chem 1995, 270: 26802-6.
38. Sun, J., Qian, Y., Hamilton, A.D., Sebti, S.M. Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res 1995, 55: 4243-7.
39. Vogt, A., Qian, Y., Blaskovich, M.A., Fossum, R.D., Hamilton, A.D., Sebti, S.M. A non-peptide mimetic of ras-CAAX: Selective inhibition of farnesyltransferase and ras processing. J Biol Chem 1995, 270: 660-4.
40. Augeri, D.J., O'Connor, S.J., Janowick, D. et al. Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase. J Med Chem 1998, 41: 4288-300.
41. Williams, T.M., Ciccarone, T.M., MacTough, S.C. et al. Design and biological activity of a series of small, low molecular weight farnesyl protein transferase inhibitors. Proc Am Assoc Cancer Res 1995, 36: Abst 2612.
42. Williams, T.M., Ciccarone, T.M., MacTough, S.C. et al. 2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, noncarboxylic acid inhibitors of farnesyl transferase. J Med Chem 1996, 39: 1345-8.
43. Leonard, D.M., Shuler, K.R., Poulter, C.J. et al. Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyl transferase. J Med Chem 1997, 40: 192-200.
44. Bolton, G.L., Creswell, M.W., Hodges, J.C., Gowan, R.C., Scholten, J., Sebolt-Leopold, J.S. The SAP of tripeptide inhibitors of ras farnesylprotein transferase. 209th ACS Natl Meet (April 2-6, Anaheim) 1995, Abst MEDI 032.
45. Bolton, G.L., Creswell, M.W., Hodges, J.C., Gowan, B.C., Scholten, J., Sebolt-Leopold, U.S. Modified peptide inhibitors of ras farnesylprotein transferase. 209th ACS Natl Meet (April 2-6, Anaheim) 1995, Abst MEDI 033.
46. Bolton, G.L, Creswell, M.W., Hodges, U.C., Gowan, B.C., Scholten, J., Sebolt-Leopold, J.S. Modified dipeptide inhibitors of ras farnesyl transferase. 25th Natl Med Chem Symp (June 18-22, Ann Arbor) 1996.
47. McNamara, D.J., Dobrusin, E., Leonard, D.M. et al. C-Terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of ras FTase, cellular activity, and anticancer activity in mice. J Med Chem 1997, 40: 3319-22.
48. Sebolt-Leopold, J.S., Gowan, R.C., Latash, M.P. et al. Cellular activity of histidinyl-(N-benzylglycinamides) against ras farnesyl transferase. Proc Am Assoc Cancer Res 1997, 38: Abst 2343.
49. Przybranowski, S.A., Sebolt-Leopold, J.S., Leonard, D. et al. In vivo evaluation of histidine-(N-benzylglycinamides) as inhibitors of ras farnesyl transferase. Proc Am Assoc Cancer Res 1997, 38: Abst 2344.
50. Bishop, W.R., Bond, R., Petrin, J. et al. Novel tricyclic inhibitor of farnesyl protein transferase: Biochemical characterization and inhibition of ras modification in transfected Cos cells. J Biol Chem 1995, 270: 30611-8.
51. Mallams, A.K., Njoroge, F.G., Doll, R.J. et al. Antitumor 8-chlorobenzocyclohepatapyridines: A new class of selective, non-peptidic, non-sulfhydryl inhibitors of ras farnesylation. Bioorg Med Chem 1997, 5: 93-9.
52. Njoroge, F.G., Doll, R.J., Vibulbhan, V. Discovery of novel nonpeptide tricyclic inhibitors of ras farnesyl protein transferase. Bioorg Med Chem 1997, 5: 101-13.
53. Mallam, A.K., Rossman, R.R., Doll, R.J. et al. Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) piperazine. J Med Chem 1998, 41: 877-93.
54. Njoroge, F.G., Taveras, A.G., Kelly, J. et al. (+)-4-[2-[4-(8-Chloro-3, 10-dibromo-6, 11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]-pyridin-11(R)-yl)-1 -piperidinyl)-2-oxo-ethyl]-1 -piperidinecarboxamide (SCH-66336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J Med Chem 1998, 48:4890-902.
55. Njoroge, F.G., Vibulbhan, B., Pinto, P. et al. Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity. J Med Chem 1998, 41: 1561-7.
56. Janssen Pharmaceuticals NV. WO9716443.
57. Janssen Pharmaceuticals NV. WO9721701.
58. End, D., Skrzat, S., Devine, A. et al. R115777, a novel farnesyl protein transferase inhibitor (FTI): Biochemical and cellular effects in H-ras and K-ras dominant systems. Proc Am Assoc Cancer Res 1998, 39: Abst 1848.
59. Skrzat, S., Angibaud, P., Venet, M., Sanz, G., Bowden, C., End, D. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI) with potent oral antitumor activity. Proc Am Assoc Cancer Res 1998, 39: Abst 2169.